These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16431128)

  • 1. Influence of short-term glucocorticoid therapy on regulatory T cells in vivo.
    Sbiera S; Dexneit T; Reichardt SD; Michel KD; van den Brandt J; Schmull S; Kraus L; Beyer M; Mlynski R; Wortmann S; Allolio B; Reichardt HM; Fassnacht M
    PLoS One; 2011; 6(9):e24345. PubMed ID: 21912688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on Regulatory T Cell Therapies.
    Probst-Kepper M; Kröger A; Garritsen HS; Buer J
    Transfus Med Hemother; 2009; 36(5):302-308. PubMed ID: 21076548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory T cells, a potent immunoregulatory target for CAM researchers: modulating tumor immunity, autoimmunity and alloreactive immunity (III).
    Vojdani A; Erde J
    Evid Based Complement Alternat Med; 2006 Sep; 3(3):309-16. PubMed ID: 16951715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory CD4
    LeGuern C; Markmann JF
    Front Immunol; 2024; 15():1293892. PubMed ID: 38404584
    [No Abstract]   [Full Text] [Related]  

  • 5. Tetramerization of pyruvate kinase M2 attenuates graft-versus-host disease by inhibition of Th1 and Th17 differentiation.
    Wang M; Li QJ; Zhao HY; Zhang JL
    Hum Cell; 2024 May; 37(3):633-647. PubMed ID: 38416276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies.
    Chen TT; Lin CC; Lo WJ; Hsieh CY; Lien MY; Lin CH; Lin CY; Bai LY; Chiu CF; Yeh SP
    Int J Hematol; 2022 Apr; 115(4):525-533. PubMed ID: 35226308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reconstitution and clinical significance of T cell subsets in the early stage after related HLA-mismatched peripheral blood hematopoietic SCT without T-cell depletion in vitro.
    Pang N; Duan X; Jiang M; Qu J; Yuan H; Xu J; Cao H; Chen G
    Int J Clin Exp Pathol; 2015; 8(8):8892-901. PubMed ID: 26464630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Umbilical cord blood-derived mesenchymal stem cells ameliorate graft-versus-host disease following allogeneic hematopoietic stem cell transplantation through multiple immunoregulations.
    Wu QL; Liu XY; Nie DM; Zhu XX; Fang J; You Y; Zhong ZD; Xia LH; Hong M
    J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):477-484. PubMed ID: 26223913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302.
    Bolaños-Meade J; Wu J; Logan BR; Levine JE; Ho VT; Alousi AM; Weisdorf DJ; Luznik L;
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):481-5. PubMed ID: 23247045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.
    Zhou J; Bashey A; Zhong R; Corringham S; Messer K; Pu M; Ma W; Chut T; Soiffer R; Mitrovich RC; Lowy I; Ball ED
    Biol Blood Marrow Transplant; 2011 May; 17(5):682-92. PubMed ID: 20713164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease.
    Fall-Dickson JM; Mitchell SA; Marden S; Ramsay ES; Guadagnini JP; Wu T; St John L; Pavletic SZ;
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):948-956. PubMed ID: 20139026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?
    Storb R; Antin JH; Cutler C
    Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S18-27. PubMed ID: 19857584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.
    Heimberger AB; Sampson JH
    Expert Opin Biol Ther; 2009 Aug; 9(8):1087-98. PubMed ID: 19591631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation.
    Zorn E; Mohseni M; Kim H; Porcheray F; Lynch A; Bellucci R; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Biol Blood Marrow Transplant; 2009 Mar; 15(3):382-8. PubMed ID: 19203731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.
    Feng X; Hui KM; Younes HM; Brickner AG
    Trends Immunol; 2008 Dec; 29(12):624-32. PubMed ID: 18952501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.
    Rezvani AR; Storb RF
    J Autoimmun; 2008 May; 30(3):172-9. PubMed ID: 18242060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonotypic analysis of T cell reconstitution after haematopoietic stem cell transplantation (HSCT) in patients with severe combined immunodeficiency.
    Okamoto H; Arii C; Shibata F; Toma T; Wada T; Inoue M; Tone Y; Kasahara Y; Koizumi S; Kamachi Y; Ishida Y; Inagaki J; Kato M; Morio T; Yachie A
    Clin Exp Immunol; 2007 Jun; 148(3):450-60. PubMed ID: 17374134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation.
    Zorn E
    Semin Cancer Biol; 2006 Apr; 16(2):150-9. PubMed ID: 16431128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.